EcoDrugPlus

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSCVAG00000019388
Gene Symbol: HTR7
3 Cross references
197 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSCVAG00000007928
Gene Symbol: LOC107089992
4 Cross references
338 Possible Orthologues:

60s Ribosomal Protein L19-Like

Ensembl ID : ENSCVAG00000012653
Gene Symbol: LOC107084780
3 Cross references
317 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSCVAG00000020721
Gene Symbol: LOC107100395
3 Cross references
383 Possible Orthologues:

60s Ribosomal Protein L22-Like

Ensembl ID : ENSCVAG00000016334
Gene Symbol: LOC107085164
2 Cross references
371 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSCVAG00000013291
Gene Symbol: LOC107086468
3 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L3

Ensembl ID : ENSCVAG00000015102
Gene Symbol: LOC107097254
3 Cross references
338 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSCVAG00000022319
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSCVAG00000022011
Gene Symbol: ADAM17
3 Cross references
210 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSCVAG00000019836
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSCVAG00000020581
Gene Symbol: ADRM1
3 Cross references
193 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSCVAG00000013407
Gene Symbol: AKT1
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).